Gilead Sciences Inc. (GILD)

66.89
NASDAQ : Health Technology
Prev Close 67.17
Day Low/High 66.45 / 67.47
52 Wk Low/High 60.32 / 79.61
Avg Volume 6.96M
Exchange NASDAQ
Shares Outstanding 1.27B
Market Cap 85.41B
EPS 4.20
P/E Ratio 9.54
Div & Yield 2.52 (3.52%)

Latest News

Gilead Sciences To Provide Free Truvada For PrEP® To Support U.S. Initiative To End The HIV Epidemic

Gilead Sciences To Provide Free Truvada For PrEP® To Support U.S. Initiative To End The HIV Epidemic

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it will donate Truvada for PrEP ® (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets) to the U.

Gilead Sciences And Goldfinch Bio Announce Strategic Collaboration To Develop Novel Therapies For Kidney Disease

Gilead Sciences And Goldfinch Bio Announce Strategic Collaboration To Develop Novel Therapies For Kidney Disease

Gilead Sciences, Inc. (Nasdaq: GILD) and Goldfinch Bio, Inc.

Gilead Sciences To Present At The Bank Of America Merrill Lynch 2019 Health Care Conference On Tuesday, May 14

Gilead Sciences To Present At The Bank Of America Merrill Lynch 2019 Health Care Conference On Tuesday, May 14

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Robin L.

Gilead Sciences Has Right Prescription on First-Quarter Earnings

Gilead Sciences Has Right Prescription on First-Quarter Earnings

Gilead Sciences' adjusted earnings in the first quarter beat analysts' expectations.

Gilead Sciences Is Regaining Its Shine

Gilead Sciences Is Regaining Its Shine

Revenue is stabilizing with new treatment lines, and this stock may be a soon be a buy.

Gilead Sciences Announces Second Quarter 2019 Dividend

Gilead Sciences Announces Second Quarter 2019 Dividend

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared a cash dividend of $0.

Gilead Sciences Announces First Quarter 2019 Financial Results

Gilead Sciences Announces First Quarter 2019 Financial Results

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter ended March 31, 2019.

Qualcomm, Dow Inc., Square, Beyond Meat, Jerome Powell - 5 Things You Must Know

Qualcomm, Dow Inc., Square, Beyond Meat, Jerome Powell - 5 Things You Must Know

U.S. stock futures are higher, rebounding from declines in the previous session after a policy statement from the Federal Reserve suggested U.S. interest rates likely will remain unchanged for the better part of the year; Qualcomm tumbles after forecasting weaker-than-expected third-quarter revenue; Square issues a weak earnings forecast for the second quarter; Beyond Meat's IPO is priced at $25 a share.

Gilead Sciences Expected to Earn $1.61 a Share

Gilead Sciences Expected to Earn $1.61 a Share

Gilead Sciences revenue expected to rise 4.1% to $5.3 billion.

Gilead Sciences' Chief Financial Officer Robin Washington To Step Down In Early 2020

Gilead Sciences' Chief Financial Officer Robin Washington To Step Down In Early 2020

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Robin Washington, Executive Vice President (EVP) and Chief Financial Officer (CFO), plans to retire from her role, effective March 1, 2020.

Feels Like Deja Tuesday

Friday felt a lot like Tuesday -- in that it didn’t change any of the big indicators -- but we should still pay close attention to the Citigroup Panic/Euphoria Index, which is now kissing the underside of Euphoria.

Gilead Announces Topline Data From Phase 3 STELLAR-3 Study Of Selonsertib In Bridging Fibrosis (F3) Due To Nonalcoholic Steatohepatitis (NASH)

Gilead Announces Topline Data From Phase 3 STELLAR-3 Study Of Selonsertib In Bridging Fibrosis (F3) Due To Nonalcoholic Steatohepatitis (NASH)

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that STELLAR-3, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an investigational, once daily, oral inhibitor of apoptosis...

Kite Announces Plans For New State-of-the-Art Facility To Expand Cell Therapy Production Capabilities

Kite Announces Plans For New State-of-the-Art Facility To Expand Cell Therapy Production Capabilities

Kite, a Gilead Company (Nasdaq: GILD), today announced plans for a new facility in Frederick County, Maryland, which will produce innovative cell therapies for people with cancer.

Gilead Sciences To Release First Quarter 2019 Financial Results On Thursday, May 2, 2019

Gilead Sciences To Release First Quarter 2019 Financial Results On Thursday, May 2, 2019

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2019 financial results will be released on Thursday, May 2, after the market closes.

The Economy is Riding the Rails: Cramer's 'Mad Money' Recap (Wednesday 4/17/19)

The Economy is Riding the Rails: Cramer's 'Mad Money' Recap (Wednesday 4/17/19)

If you want a good read on the economy, look at the details of CSX's latest earnings report.

Nvidia, Advanced Micro Devices, Constellation: 'Mad Money' Lightning Round

Nvidia, Advanced Micro Devices, Constellation: 'Mad Money' Lightning Round

Jim Cramer weighs in on Nvidia, Advanced Micro Devices, Constellation Brands, Bausch Health, Arista Networks, Gilead Sciences and more.

Are These Stocks the Best of the Best?

Are These Stocks the Best of the Best?

Screening Goldman Sachs' list of the top 20 stocks to see which ones are the best technical opportunities.

Gilead And Insitro Announce Strategic Collaboration To Discover And Develop Novel Therapies For Nonalcoholic Steatohepatitis

Gilead And Insitro Announce Strategic Collaboration To Discover And Develop Novel Therapies For Nonalcoholic Steatohepatitis

Gilead Sciences Inc. (Nasdaq: GILD) and insitro announced today that the companies have entered into a strategic collaboration to discover and develop therapies for patients with nonalcoholic steatohepatitis (NASH).

Gilead Sciences Teams With Novo Nordisk for Trials of Liver Disease Drugs

Gilead Sciences Teams With Novo Nordisk for Trials of Liver Disease Drugs

Gilead Sciences is partnering with Novo Nordisk to help combat liver disease.

Gilead Sciences And Novo Nordisk Announce Intent To Initiate A Clinical Collaboration In NASH

Gilead Sciences And Novo Nordisk Announce Intent To Initiate A Clinical Collaboration In NASH

Gilead Sciences, Inc. (NASDAQ: GILD) and Novo Nordisk A/S (NASDAQ Copenhagen: NOVO B) today announced that the companies intend to collaborate on a clinical trial combining compounds from their respective pipelines in nonalcoholic steatohepatitis (NASH).

Gilead Presents New Data On Viral Hepatitis At The International Liver Congress™ 2019

Gilead Presents New Data On Viral Hepatitis At The International Liver Congress™ 2019

Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data on the use of its chronic hepatitis B (HBV) and hepatitis C (HCV) medicines including safety and efficacy data on Vemlidy ® (tenofovir alafenamide 25mg, TAF) in HBV patients previously treated...

Gilead Presents New Data In Nonalcoholic Steatohepatitis (NASH) At The International Liver Congress™ 2019

Gilead Presents New Data In Nonalcoholic Steatohepatitis (NASH) At The International Liver Congress™ 2019

Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from the company's clinical research program in nonalcoholic steatohepatitis (NASH) being presented at The International Liver Congress™ 2019 in Vienna.

Gilead Announces New Grant Programs Supporting Investigator-Sponsored Research In Liver Diseases

Gilead Announces New Grant Programs Supporting Investigator-Sponsored Research In Liver Diseases

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the launch of five new global grants programs to continue to support investigator-sponsored research in chronic hepatitis C virus (HCV) and hepatitis B virus (HBV), HCV and HIV co-infection,...

Gilead Submits Supplemental New Drug Application To U.S. Food And Drug Administration For Once-Daily Descovy® For HIV Pre-Exposure Prophylaxis

Gilead Submits Supplemental New Drug Application To U.S. Food And Drug Administration For Once-Daily Descovy® For HIV Pre-Exposure Prophylaxis

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the company has submitted a supplemental New Drug Application (sNDA) to the U.

Galapagos Soars After Rheumatoid Arthritis Drug Meets Primary Endpoint

Galapagos Soars After Rheumatoid Arthritis Drug Meets Primary Endpoint

The company's treatment, filgotinib, is being developed with Gilead Sciences.

Gilead And Galapagos Announce Filgotinib Meets Primary Endpoint In The Phase 3 FINCH 3 Study In Methotrexate-Naïve Rheumatoid Arthritis Patients

Gilead And Galapagos Announce Filgotinib Meets Primary Endpoint In The Phase 3 FINCH 3 Study In Methotrexate-Naïve Rheumatoid Arthritis Patients

regulated information - Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced Week 24 results of FINCH 3, an ongoing, randomized, double-blind, active-controlled Phase 3 study of filgotinib, an investigational,...

Gilead And Galapagos Announce Filgotinib Meets Primary And Key Secondary Endpoints In The Phase 3 FINCH 1 Rheumatoid Arthritis Study

Gilead And Galapagos Announce Filgotinib Meets Primary And Key Secondary Endpoints In The Phase 3 FINCH 1 Rheumatoid Arthritis Study

regulated information - Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced Week 24 results of FINCH 1, an ongoing, randomized, double-blind, placebo- and active-controlled Phase 3 study of filgotinib, an...

Gilead And Galapagos Report Updated Safety Information For Filgotinib In Rheumatoid Arthritis (RA)

Gilead And Galapagos Report Updated Safety Information For Filgotinib In Rheumatoid Arthritis (RA)

regulated information - Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today also announced interim safety information from four studies of the investigational compound filgotinib for the treatment of rheumatoid arthritis...

TheStreet Quant Rating: C (Hold)